



Academy of  
Managed Care  
Pharmacy®

# Patient Reported Outcomes:

## The Missing Link in Defining Value

AMCP PARTNERSHIP FORUM • OCTOBER 19, 2017 • DALLAS, TEXAS

HOSTED BY THE ACADEMY OF MANAGED CARE PHARMACY IN PARTNERSHIP WITH



Boehringer  
Ingelheim

Genentech  
*A Member of the Roche Group*



NOVARTIS  
PHARMACEUTICALS



novo nordisk®



PRECISION  
FOR VALUE



PREMIER  
TRANSFORMING  
HEALTHCARE TOGETHER®



SANOFI



Xcenda®  
AmerisourceBergen





# Welcome!

## SUSAN A. CANTRELL, RPh, CAE

AMCP Chief Executive Officer



Welcome to the Academy of Managed Care Pharmacy's (AMCP's) partnership forum on *"Patient Reported Outcomes: The Missing Link to Defining Value."*

It bears stating the obvious: patients are at the center of health care. That fact often gets overlooked in discussions on how to improve and enhance the value of our complex health care system. Sometimes we need to pause and ask a few key questions: What is the patient's perspective of their health care? How do health care stakeholders maximize the value of patient feedback? And how can the patient's perspective be used to improve the way we deliver care?

Patient reported outcomes (PROs) represent a sea change in how we look at and measure value in health care. A PRO might define value through such metrics as, "patient feels good, or patient can go back to work." Developing widely usable PROs, however, has been a challenge, given the fragmented nature of our system and the divergent perspectives of stakeholders across the health care spectrum. That is why we are here. AMCP has gathered a diverse group of experts to explore questions such as:

- What PROs are being used now?
- How can we help make PROs more useable?
- What meaningful PROs define value?
- How do we ensure that PROs are being met?
- How do we make sure that PROs are reflected in the development and reimbursement of drugs and devices to drive meaningful outcomes?
- In what settings are PROs applicable today and where will they be applicable tomorrow?

Together, we have made great strides in improving "value," including through identifying optimal therapies based on best-available evidence, and adopting the latest medication therapy management practices. But such value propositions are for naught if the patient declines to take a medication, or believes the treatment is not improving their health.

AMCP will use the forum's recommendations to advance health care stakeholders' efforts to engage patients, gather usable PROs, and ultimately use those findings to improve health outcomes. I would like to personally thank the following organizations for their support in making this event possible: Amgen, Boehringer Ingelheim, Genentech, GSK, Novartis, Novo Nordisk, Precision For Value, Premier, Sanofi, Takeda, and Xcenda. I look forward to your participation.

Sincerely,

Susan A. Cantrell, RPh CAE  
AMCP Chief Executive Officer



# Agenda:

8:00 AM – 9:00 AM

Welcome and Introductions

9:00 AM – 9:45 AM

**DISCUSSION:**  
How do Patient Reported Outcomes Support the Mission of Your Organization?

9:45 AM – 10:00 AM

**BREAK**

10:00 AM – 10:45 AM

**PANEL:**  
Exploring the Developments in Patient Reported Outcomes for Drug Approvals and Quality Measures

10:45 AM – 11:00 AM

**BREAK**

11:00 AM – 11:45 AM

**PANEL:**  
Addressing Obstacles that Impact Patient Reported Outcomes Utilization

11:45 AM – 12:30 PM

**BREAKOUT SESSION:**  
Creating the Future State of Patient Reported Outcomes

12:30 AM – 1:00 PM

**LUNCH**

1:00 PM – 1:45 PM

**REPORT OUT:**  
Future State of Patient Reported Outcomes

1:45 PM – 2:45 PM

**BREAKOUT SESSION:**  
Making the Future State a Reality

2:45 PM – 3:30 PM

**BREAKOUT SESSION:**  
AMCP Patient Reported Outcomes Survey

3:30 PM – 4:00 PM

Defining Next Steps





## JOEL V. BRILL, MD, FACP

*Chief Medical Officer  
Predictive Health*

Joel V. Brill is an executive clinician with over 30 years of experience providing strategic leadership and medical oversight to large data-driven health organizations. He is skilled in strategy, development and implementation of innovative health programs, products and payment systems, with extensive experience in clinical practice, research, coverage, reimbursement, quality improvement, data analysis, bundled and episode payments and accountable care.

Dr. Brill is Board Certified in Internal Medicine and Gastroenterology, and serves as the Chief Medical Officer of Predictive Health. He has run risk-bearing Independent Practice Associations and Physician-Hospital Organizations in California and Arizona, held management positions and currently participates on Scientific Advisory Boards and Committees for several managed care companies. He was the Deputy Medical Director for the BFCC.NCC-QIO oversight project, was Section Editor for GI & Hepatology News, serves on the Editorial Advisory Board for several journals, and the co-founder of the AGA Center for GI Innovation and Technology.

He also works extensively with the Centers for Medicare and Medicaid Services (CMS) and the American Medical Association (AMA) on coding, coverage and reimbursement issues, and co-Chaired the Part D medication measures Technical Expert Panel for CMS. He participates in the CPT Editorial Panel and the AMA RBRVS Update Committee (RUC), and has introduced over 180 CPT coding proposals. He has published extensively on episode and bundled payment methodologies, and has developed and submitted advanced payment models to the HHS Physician Focused Payment Model Technical Advisory Committee for consideration under MACRA.

In addition, Dr. Brill serves as an Assistant Clinical Professor of Medicine at the University of Arizona College of Medicine, and an Adjunct Assistant Professor of Medicine at Midwestern University. He has lectured at the School of Health Management & Policy at the WP Carey School of Business at Arizona State University.

He received his undergraduate A.B. Biology at the University of California, Los Angeles, and graduated from the Rosalind Franklin University of Medicine and Science – Chicago Medical School. He completed his Internship and Residency in Internal Medicine at the UCLA – San Fernando Valley Program, and a fellowship in Gastroenterology at Los Angeles County – USC Medical Center. Dr. Brill completed the Management Program for Health Care Organizations at the UCLA School of Public Health.




Pioneering science delivers vital medicines™

## *Transforming the language of life into **vital medicines***

At Amgen, we believe that the answers to medicine's most pressing questions are written in the language of our DNA. As pioneers in biotechnology, we use our deep understanding of that language to create vital medicines that address the unmet needs of patients fighting serious illness – to dramatically improve their lives.

For more information about Amgen, our pioneering science and our vital medicines, visit [www.amgen.com](http://www.amgen.com).





### AMANDA BAIN, PharmD, MPH, MBA

*Director, Pharmacy and Care Management  
The Ohio State University Health Plan, Inc.*

Amanda Bain is Director of Pharmacy and Care Management for The Ohio State University Health Plan, Inc. in Columbus, Ohio. She leads the creation, implementation and evaluation of nursing and pharmacy care management programs. Additionally, she acts as the clinical liaison to the Office of Human Resources, the OSU Wexner Medical Center, and the PBM vendor in support of pharmacy benefit program designs, services, and communications for The Ohio State University. She has served on numerous national committees regarding pharmacy education, quality, and technology.



### KRISTEN BINASO

*Director of Patient Advocacy and Professional Relations for Cardiovascular, Metabolics, Respiratory and ILD  
Boehringer Ingelheim Pharmaceuticals, Inc.*

Kristen Binaso leads a team that is responsible for building and maintaining collaborative partnerships with key patient advocacy groups and professional medical associations at the global, national and regional level. The team focuses on patient engagement and opportunities to highlight the patient voice through various company initiatives. Prior to working at Boehringer Ingelheim, her experiences include working at the American Pharmacists Association in Washington, D.C., in Corporate Alliances, and extensive experience in pharmacy operations and professional/college relations and recruitment with CVS/Pharmacy, Rite Aid and Target.




### HOLLY BUDLONG, PharmD, PHD

*Health Outcomes Manager  
Fairview Pharmacy Services*

Dr. Holly Budlong serves as the Health Outcomes Manager for Fairview Pharmacy Services, a leading health system based pharmacy organization in Minneapolis, MN. As Health Outcomes Manager, Holly is responsible for developing FPS' outcomes strategy, building capabilities and leading outcomes projects across all of Fairview Pharmacy's business units. In addition, she holds an Adjunct Assistant Professorship at the University of Minnesota College of Pharmacy in Social and Administrative Pharmacy.



# Nurturing innovative ideas today for more health tomorrow.



Boehringer Ingelheim ranks among the world's 20 leading pharmaceutical corporations. Our vision drives us forward. It helps us to foster value through innovation in our company and to look to the future with constantly renewed commitment and ambition.

For more than 125 years, Boehringer Ingelheim has been committed to the research and development of innovative medicines that help make more health for patients and their families.

Visit us online at  
[us.boehringer-ingelheim.com](http://us.boehringer-ingelheim.com)





### RACHEL CLARK SISODIA, MD

*Assistant Professor and Medical Director for the Massachusetts General Physician Organization  
Harvard Medical School/Massachusetts General Hospital*

Dr. Rachel M. Clark is a Gynecologic Oncologist on staff at Massachusetts General Hospital (MGH) and an Assistant Professor of Obstetrics, Gynecology and Reproductive Endocrinology at Harvard Medical School. In addition to clinical care, she is a Medical Director for the Massachusetts General Physician Organization. In her capacity as a Medical Director at MGH, she oversees a variety of population health initiatives as well as various risk sharing contracts with CMS and payers. Her responsibilities include oversight of all Patient Reported Outcomes (PRO) at MGH as well as at-risk monies regarding MGH's performance on these measures. MGH has PROs launched in over 50 clinics.



### DEB CURRY, PharmD

*Sr. Director, Formulary Product Strategy  
OptumRx*

Deb Curry currently serves as Senior Director, Formulary Product Strategy at OptumRx, where she is responsible for formulary and clinical operations and strategy for the Commercial, Medicaid and Insurance Exchange populations. Deb serves as a voting and non-voting member on Medicare and non-Medicare P&T committees and is heavily involved in OptumRx's specialty program, pipeline management, product development and clinical strategy. Prior to joining OptumRx, Deb worked at two regional health plans and in pharma. Currently, Deb serves on the Board of Directors for the Academy of Managed Care Pharmacy. She has presented or published on various topics, including extensive work on prescription drug benefits in health care reform.



### BAHAR DAVIDOFF, PharmD

*Vice President of Pharmacy  
Regal Medical Group*

Bahar Davidoff is the Vice President of Pharmacy at Regal Medical Group, which is one of the largest networks of physicians and specialist in Southern California. Dr. Davidoff oversees a clinical pharmacy team providing strategic direction for formulary management, utilization management, operations and all clinical programs. She has implemented high quality pharmaceutical care by providing a broad scope of services that meet the needs of the patients, the medical community, and the organization. Under her direction, her team ensures optimal use of medications through Medication Therapy Management and disease management. Dr. Davidoff also oversees an active Pharmacy and Therapeutics Committee, interdepartmental programs, and continuity of care initiatives. In addition, she serves as a co-chair for the CAPG pharmaceutical committee and is an active member of the Rite Care Initiative.



TRINITY ALFARO  
Trinity has type 1 diabetes

# UNDERSTANDING SUPPORT

## passion for improving patient lives

As a leader in diabetes care, we strive to provide optimal care for patients and to put their needs at the center of everything we do.

Making a positive difference in people's lives is at the heart of everything Novo Nordisk does – through groundbreaking science, sustained focus on the environment, and patient-centered care.

For more about us, visit [novonordisk.us](http://novonordisk.us).



### MICHELE V. DAVIDSON, RPh

*Sr. Manager, Pharmacy Technical Standards, Policy & Development  
Walgreens*

Michele V. Davidson is currently Senior Manager of Pharmacy Technical Standards, Development and Policy for the Walgreens Company. As a member of the Walgreens policy team she follows legislation that may affect pharmacy technology, engages industry thought leaders to propose needed changes, and provides guidance to the Walgreens state government relations team on state policy issues. She also acts as a liaison within Walgreens to ensure company engagement in National Council of Prescription Drug Programs. Prior to joining Walgreens in 2009, she worked for the National Association of Chain Drug Stores as the Director of Telecommunication Standards. She had 26 years' experience with Eckerd Drugs.



### JESSICA DAW, PharmD, MBA

*Senior Director, Clinical Pharmacy  
UPMC Health Plan*

Jessica Daw is the Senior Director, Clinical Pharmacy at UPMC Health Plan. Her primary responsibilities include managing the pharmacy clinical programs for Medicare, Special Needs, Medical Assistance, Commercial, Exchange, and the Children's Health Insurance products. Her role includes formulary and utilization management as well as clinical program and pharmacy care management program development. Jessica participates as a member of the Educational Affairs Committee and as a past Chair of the Professional Practice Committee for the Academy of Managed Care Pharmacy to provide input on the professional and educational direction of members.



### JOSEPH DICESARE, RPh, MPH

*Head, HE&OR Early Products  
Novartis Pharmaceuticals Corp.*

Joe DiCesare is currently the head of the U.S. Health Economics & Outcomes Research Neuroscience, Respiratory, and Ophthalmology franchises at Novartis Pharmaceuticals. Joe's team is responsible for developing and implementing HE&OR strategies for products in these therapeutic areas. Prior to moving into his current role, Joe was the Global Head of Strategic Pricing and Access in the Novartis Oncology Business Unit. He previously also led the Novartis Global HE&OR department and U.S. HE&OR department. Joe worked in clinical development at Novartis/Sandoz and at Knoll/Abbott Pharmaceuticals before moving into the HE&OR area. Joe is currently an Adjunct Professor at Rutgers College of Pharmacy and serves on corporate advisory boards at Tufts University and the University of Washington.





We live here and work here. No wonder we know all the roads leading to commercial success.

The landscape may seem foreign to some, but as former payers ourselves we see insights others miss. Unlike those who offer up little but theories and unproven opinions on market access drivers, Precision for Value provides real-world payer perspectives. Combine these with insights from academia, and you can be confident you'll get what decision makers desire most—relevant value propositions, innovative reimbursement strategies, and precise pull-through that lead to commercial success for your brand. [precisionforvalue.com](https://precisionforvalue.com)







### SARAH DONELSON, MA

*Lead, Patient-Centered Research & Collaboration  
Genentech*

Sarah Donelson is passionate about understanding the patient's perspectives, quantifying their experience and demonstrating outcomes to improve the health care system. She has spent the last 15 years in the pharmaceutical industry, where she created the Patient-Reported Outcomes development team at Genentech and now leads Patient-Centered Research program in US Medical Affairs. She was a founding member of the Critical Path Patient-Reported Outcomes Consortium and has been a senior scientist for numerous instrument development projects as well as studies investigating emerging technology's ability to quantify patient experience. The enduring focus of her work is to elevate the voice of the patient to the level of evidence for health services research and policy-making.



### SETH GINSBERG

*Co-Founder  
Global Healthy Living Foundation (GHLF)*

Seth Ginsberg is an international health advocate and thought leader based in New York City. Ginsberg was diagnosed in 1994 with Spondylarthritis, and in 1999, at age 18, he helped pioneer the world's first online patient community for the millions of people worldwide suffering from arthritis, called CreakyJoints. CreakyJoints has grown into a trusted and recognized web site and patient community, delivering robust patient education, community-based and web-based support, advocacy initiatives and patient-centered research. In 2007, Ginsberg and social entrepreneur Louis Tharp co-founded the Global Healthy Living Foundation, the 501(c)(3) non-profit parent organization of CreakyJoints and related advocacy campaigns. CreakyJoints Australia, also lead by Ginsberg, is the first international patient community under the GHLF umbrella, and constitutes a growing and vibrant community of patients throughout Australia. Since 2014, Ginsberg has served as a Principal Investigator of the PCORI-funded patient powered research network ArthritisPower®.



### DOUGLAS GOLDSTEIN

*AVP, Innovation Officer  
Inova Center for Personalized Health*

Douglas Goldstein is a dynamic executive, innovator and futurist. He also serves as the AVP, Innovation Officer for the Inova Center for Personalized Health which is transforming the former world HQ for Exxon Mobil into a leading health and wellness district. At Inova, Doug is responsible for developing the next generation of outcomes and value based relationships that apply precision medicine, mobile and social factors to improve population health. As the eFuturist, he has authored 11 books on health care management and technology including "Building Medical Staff Alliances," "eHealthcare," "Best of the Net Online Guides" and "Medical Informatics 20/20." As a sought after motivational speaker he has been on the cutting edge of innovation for 25 years as he delivered hundreds of keynotes and leading health innovations.



# EXPANDING OUR SPECIALTY PHARMACY FOOTPRINT

Commcare Specialty Pharmacy and Acro Pharmaceutical Services now work together as Premier Inc. companies.



Greater  
Medication Access



Increased Access  
to Payers, Patients  
and Providers



Providing More  
Choices for Customers

## DELIVERING WHAT YOU NEED – EXCEPTIONAL SERVICE AND SUPPORT

- 24/7 Clinical Pharmacist Support
- Best-In-Class Medication Adherence Rates
- Assist Disease State Management Programs
- High Touch Personalized Patient Care
- >95 Percent Patient/Provider Satisfaction Rate
- Free and Confidential Home Delivery



888.203.7973 | [www.commcarepharmacy.com](http://www.commcarepharmacy.com)



800.906.7798 | [www.acropharmacy.com](http://www.acropharmacy.com)





### HILARY HATCH, PhD

*Founder and CEO  
Vital Score*

Dr. Hilary Hatch is founder and CEO of Vital Score. As a clinical psychologist and psychoanalyst, and Instructor of Medicine at Johns Hopkins, she is recognized thought leader on patient engagement. Vital Score supports innovative health systems and health plans in patient-driven quality. In 3-minute digital conversations during wait time in provider visits, Vital Score's proprietary Motivational Indexing™ model increases up to 20x the rates of patient participation in vaccines, diabetes prevention, smoking cessation, palliative care and medication adherence.



### JOHN KALADA

*Vice President, Market Access Consulting  
and Communications  
Xcenda*

John Kalada is Vice President of the Market Access Consulting and Communications group for Xcenda. John has over 30 years of industry experience that includes both the pharmaceutical/biotech and consulting services industries, with over 20 years of these experiences in the pharmaceutical/biotech industry in a variety of positions including sales, marketing, operations, market research, market access, and business development. Mr. Kalada has spent the past 11 years leading consulting teams in helping life-sciences manufacturers navigate the challenges and opportunities within the market access arena and guiding these clients to commercialization success.



### FRANCIS KALUSH, PhD

*Programs Health Coordinator  
FDA/CDER*

Dr. Francis Kalush is the Health Programs Coordinator in the Professional Affairs and Stakeholder Engagement (PASE) at the Office of the Center Director, Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA). She provides a focal point for advocacy, to enhance two-way communication and collaboration with health-care professionals, patients, patient groups, and others on CDER issues concerning drug development, drug review, and drug safety. Dr. Kalush provides leadership and strategic planning direction for educating, developing, communicating, implementing, and assessing advocacy and stakeholder relations strategy for CDER. She is CDER's Network of Experts Coordinator.





More than **18,000**  
employees in the United States

**A comprehensive offering** of  
medicines, vaccines and  
innovative services all over  
the world

More than **120** locations  
across North America

© Blue Images/Corbis - ooyoo/Getty Images

## SANOFI FOCUSED ON PATIENTS' NEEDS

Over the years, Sanofi has evolved to meet the new challenges of healthcare worldwide. Today, Sanofi is a global healthcare leader focused on patients. We listen to their needs, treat them, and provide support to them. Through our diversified portfolio of medicines, vaccines and innovative therapeutic solutions, we strive to protect the health and meet the needs of the world's 7 billion people.

US.COR.14.06.005



For more information: [www.sanofi.com](http://www.sanofi.com) – [www.sanofi.us](http://www.sanofi.us)

[www.facebook.com/sanofiUS](https://www.facebook.com/sanofiUS)  [www.twitter.com/sanofiUS](https://www.twitter.com/sanofiUS)  [www.pinterest.com/sanofiUS](https://www.pinterest.com/sanofiUS) **SPEAKING OF SANOFI**  [blog.sanofi.us](http://blog.sanofi.us)



### GEORGE KITCHENS, RPh

*President  
Artia Solutions LLC*

George Kitchens currently is President of Artia Solutions LLC, a consulting firm specializing in assisting pharmaceutical companies gain and protect access in Medicaid and VA/DoD. His experience includes Regional Operations Manager for Eckerd Drugs, Pharmacy Bureau Chief for Florida Medicaid, and VP of Business Development for Provider Synergies. Notable accomplishments include (1) creating the first pharmaceutical care network (MTM) for a pharmacy chain, Eckerd Drugs (2) Creating the first Medicaid Preferred Drug List (3) Creating the TOP\$ purchasing pool.



### ROSS MACLEAN, MD

*SVP, Head of Medical  
Precision Health Economics*

Dr. Ross Maclean is Senior Vice President, Head of Medical at Precision Health Economics (PHE), a Precision for Value health care consulting company. PHE is a market leader in health economics and outcomes research. Dr. Maclean has contributed to more than 75 articles appearing in peer-reviewed journals such as *Archives of Internal Medicine*, *The American Journal of Managed Care*, *Journal of Occupational and Environmental Medicine*, *Journal of Medical Economics*, and *Health Affairs* across a broad spectrum of topics, including telemedicine, healthcare quality, diabetes, kidney transplantation, and rheumatoid arthritis.



### ROBERT MCBURNEY, PhD

*Chief Executive Officer  
Accelerated Cure Project for Multiple Sclerosis*

Dr. Robert McBurney is the CEO of the Accelerated Cure Project for Multiple Sclerosis and the Co-Principal Investigator for the iConquerMS™ Patient-Powered Research Network. In a career spanning more than 35 years, Robert has conducted basic and clinical research and managed research groups for drug discovery, personalized medicine, and clinical decision support systems at medical schools, research institutes, biopharmaceutical companies and non-profit organizations in Australia, the U.K. and the USA. Robert is currently a member of the American Academy of Neurology, the Society for Neuroscience, the PhRMA Foundation Informatics Advisory Committee and the International Society for Pharmacoeconomics and Outcomes Research. He is also a Trustee Emeritus of the F.W. Olin College of Engineering.





## Better Health, Brighter Future

There is more that we can do to help improve people's lives. Driven by passion to realize this goal, Takeda has been providing society with innovative medicines since our foundation in 1781.

Today, we tackle diverse healthcare issues around the world, from prevention to care and cure, but our ambition remains the same to find new solutions that make a positive difference, and deliver medicines that help as many people as we can, as soon as we can.

With our breadth of expertise and our collective wisdom and experience, Takeda will always be committed to improving the future of healthcare.



### MICHELLE MOCARSKI, MPH

*Director, Health Economics and Outcomes Research  
Novo Nordisk*

Michelle Mocarski is a Director of Health Economics and Outcomes Research at Novo Nordisk, Inc. where her work focuses on the study of diabetes and diabetes treatments. In her previous role at Forest Research Institute, she was involved in the development of two patient-reported outcome measures for COPD. She also previously served as part of the Critical Path Institute's PRO Consortium — most notably as Co-Chair of the Asthma Working Group and the Process Subcommittee.



### DAVID NILASENA, MD, MSPH, MS

*Chief Medical Officer, Region VI  
Centers for Medicare & Medicaid Services*

Dr. David Nilasena is the Chief Medical Officer for the U.S. Centers for Medicare & Medicaid Services' Dallas Regional Office. He has been with the agency since 1995. He is the regional lead for the agency's Value-Based Purchasing initiatives, including quality reporting and pay for performance programs in hospitals, ambulatory surgical centers and ambulatory care settings. He is also a lead contact for the HITECH EHR Incentive Programs and the Quality Payment Program (QPP) and is also part of the regional team implementing the Health Insurance Marketplace. Dr. Nilasena has been the CMS lead for national quality improvement efforts in acute myocardial infarction, heart failure and stroke. He has served as a clinical and technical consultant to Quality Improvement Organizations and End Stage Renal Disease Networks in CMS Region 6.



### SALLY OKUN, RN, MMHS

*VP Advocacy, Policy & Patient Safety  
PatientsLikeMe*

Sally Okun is Vice President for Advocacy, Policy and Patient Safety at PatientsLikeMe. Sally joined the company in 2008 as manager of Health Data Integrity. She is responsible for bringing patient voice and insight to diverse advocacy and health policy discussions at the national and global level, and is the company's liaison with external organizations, government and regulatory agencies. She is frequently sought to represent the patient perspective at numerous external activities, advisory boards and expert panels. In 2017 she joined the Board of Directors for Public Responsibility in Medicine and Research (PRIM&R).



# INSPIRATION

In a marketplace where demands for data and differentiation are high, choose a market access partner that can turn your hard work into an inspiring story.

*Choose Xcenda.*

With scientific rigor as a foundation, along with innovative thinking and creative expertise, Xcenda helps uncover and transform evidence into an impactful value proposition that matters to payers and maximizes access to your product. Together, let's inspire success.

Visit us at [www.xcenda.com](http://www.xcenda.com)







### LISA OIPARI-ARRIGAN, PhD

*Associate Professor  
Cincinnati Children's Hospital Medical Center*

Dr. Lisa Oipari-Arrigan is an Associate Professor of Pediatrics at Cincinnati Children's Hospital Medical Center in the Anderson Center for Health Systems Excellence and Behavioral Medicine and Clinical Psychology. Dr. Oipari-Arrigan is a behavioral scientist and clinical psychologist with a research focus on development and implementation of mobile health technology to improve chronic care delivery, as well as interventions to facilitate patient-clinician co-production of healthcare. She is a Principal Investigator on multiple studies involving the design and testing of mobile health tools to capture real time patient reported outcomes and integrate them into more continuous models of chronic care delivery within learning health systems.



### MATTHEW PICKERING, PharmD

*Associate Director, Research & Quality Strategies  
Pharmacy Quality Alliance*

Dr. Matthew K. Pickering serves as the Associate Director of Research & Quality Strategies at the Pharmacy Quality Alliance (PQA). In this role, Dr. Pickering is responsible for coordinating research and demonstration project portfolios, including medication adherence initiatives and one of its flagship projects, ImmuSMART, a research study to improve adult immunization rates. Additionally, Dr. Pickering identifies needed studies to further validate the impact of PQA's measures on improving patient care, reducing overall healthcare spending, and filling recognized gaps in performance measurement.



### AISHA T. PITTMAN, MPH

*Senior Director of Quality Policy and Analysis  
Premier, Inc.*

Aisha Pittman is responsible for providing expertise to help Premier members understand, shape and effectively operate within the changing environment in regard to performance measurement, quality and payment programs. Ms. Pittman has over 14 years in health care quality and policy. Her experience includes implementing quality improvement activities as the AVP of Quality at CenterLight Healthcare. As Senior Director at the National Quality Forum, she led efforts to provide multi-stakeholder pre-rulemaking input on federal quality programs. As Chief of Health Plan Quality at the Maryland Health Care Commission, she had oversight of state quality efforts. As Senior HealthCare Analyst at the National Committee for Quality Assurance, she developed performance measures and evaluation approaches.

APRIL 23–26 • BOSTON CONVENTION AND EXHIBITION CENTER



# AMCP MANAGED CARE & SPECIALTY PHARMACY ANNUAL MEETING 2018

The AMCP Managed Care & Specialty Pharmacy Annual Meeting is all about adapting and thriving in a world of constant change and challenge. This April, in revolutionary Boston, we will bring together the experts, decision makers and thought leaders at the forefront of managed care pharmacy and health care: all for one great meeting.

- Educational sessions that deliver rich content for those who manage and evaluate drug therapies, develop and manage networks, and work with medical managers and information specialists in managed care settings.
- Networking events that allow all the facets of our field to connect, discuss, learn, and problem-solve in a dynamic, collegial setting
- Informal gatherings and meet-ups that enhance the attendee experience and afford plenty of opportunities for achieving your meeting goals

**It's the Managed Care and Specialty Pharmacy Event  
of the Year! Join us for springtime in Boston.  
Registration opens November 14<sup>th</sup>.**



Academy of  
Managed Care  
Pharmacy®

[www.amcpmeetings.org](http://www.amcpmeetings.org)





### SANDHYA SAPRA, PhD

*Director  
Amgen*

Dr. Sandhya Sapra is a director at Amgen where she has focused on strategies in support of the migraine pipeline of products since 2014. She has extensive experience in the field of health economics and outcomes research, including patient-reported outcomes (PROs). This includes experience as a consultant with Health BenchMarks and research analyst with the University of California, San Francisco. Sandhya's previous pharmaceutical industry experience includes companies such as Genentech, where she was responsible for generating value-evidence in asthma and rheumatoid arthritis, and Bristol-Myers Squibb, where she was the Director and Global Lead of early virology, responsible for developing value propositions for products treating Hepatitis C and HIV.



### LOU SANQUINI

*Vice President, Life Sciences Group  
Healthgen, division of Aetna*

Lou Sanquini leads strategy programs for Healthgen in the life sciences arena. Lou's career spans more than 20 years working in a variety of ascending positions in sales, marketing and managed care with GlaxoSmithKline and Meda pharmaceuticals. He launched and managed 11 brands while handling provider and consumer strategy. Lou led a variety of marketing, sales and business development (BD) teams. Prior to joining Healthgen, he was an executive team member for a patient engagement and recruitment company, QualityHealth, where he was responsible for marketing, innovation and BD. His work significantly contributed to the company's growth and sale to Sharecare.



### JEAN R. SLUTSKY, PA, MSPH

*Chief Engagement and Dissemination  
Officer  
PCORI*

Jean R. Slutsky is the Chief Engagement and Dissemination Officer at the Patient-Centered Outcomes Research Institute (PCORI). She leads PCORI's Engagement Program and growing dissemination and implementation planning efforts. Before joining PCORI, Jean directed the Center for Outcomes and Evidence at the Agency for Healthcare Research and Quality, where she conceived and implemented the Effective Health Care program. The Effective Health Care program is an integrated program of research, stakeholder engagement, research training, and dissemination and implementation of comparative effectiveness research. Jean is particularly interested in pragmatic user-driven research and its implementation into healthcare decision making.



### TRACY SPINKS, BBA

*Senior Director, Quality Innovation  
National Quality Forum*

Tracy Spinks is the Senior Director, Quality Innovation at National Quality Forum in Washington. Tracy leads the NQF Measure Incubator™, which promotes efficient measure development and testing through collaboration and partnership. She also leads NQF's Learning Collaborative, whose members are committed to innovation and ideation to improve quality measurement. Previously, Tracy provided financial, management, and litigation consulting services before focusing on oncology-focused health policy, quality metrics, and alternative payments.



### ROBIN TURPIN, PhD

*Value Evidence Lead  
Takeda*

Dr. Robin Turpin serves as Takeda's Value Evidence Lead, which involves anticipating changes to payment reform/MACRA, value-based insurance design, FDAMA 114, and other transformations that impact payer coverage and reimbursement decisions. She has worked for hospital and health care systems, as well as the Joint Commission on Accreditation of Healthcare Organizations where she led performance metric testing. Her industry experience includes HEOR positions with Merck, Baxter and Takeda. She has coauthored more than 100 books, book chapters, and journal articles on health economics and population health management. Robin received her PhD in Social Psychology and was a Distinguished Fellow with the National Institute of Disability and Rehabilitation Research. She has held academic appointments with Loyola University Chicago and Northwestern University Medical School, and serves on the editorial board of Population Health Management.



### MITZI WASIK, PharmD, BCPS, FCCP, FAMCP

*Stars Strategy Lead  
Aetna*

Mitzi Wasik is the Stars Business Strategy Lead for the Southeast region at Aetna. In her current role she is responsible for overseeing strategies for improving quality performance for Medicare contracts. Previously, Mitzi served as the Director of Medicare Pharmacy Clinical Programs at Aetna. She oversaw clinical pharmacy programs including Transitional Care, Comorbid Case Management, MTM, SNP, and the Part D Patient Safety Measures. She spent time in academia from 2002–2010 at both Ferris State University and University of Illinois at Chicago Colleges of Pharmacy. She has also served ten years in the Army Reserves.





**LAURIE WESOLOWICZ,**  
**PharmD, FAMCP**

*Vice President, Payor Strategies  
Diplomat Specialty Pharmacy*

Laurie Wesolowicz is Vice President, Payor Strategies at Diplomat, the largest independent specialty pharmacy in the United States. Before joining Diplomat in June 2017, she served for nine years as director of pharmacy services clinical at Blue Cross Blue Shield of Michigan. Laurie is a Fellow of the Academy of Managed Care Pharmacy. She has served as an adjunct clinical assistant professor at University of Michigan's College of Pharmacy for more than 20 years. In 2016, she was appointed to the Michigan Prescription Drug and Opioid Abuse Commission.

# Thank You to our Sponsors

**AMGEN**<sup>®</sup>

 **Boehringer  
Ingelheim**

**Genentech**  
*A Member of the Roche Group*

 **gsk**

 **NOVARTIS**  
PHARMACEUTICALS

 **novo nordisk**<sup>®</sup>

 **PRECISION<sup>™</sup>  
FORVALUE**

 **PREMIER**  
TRANSFORMING  
HEALTHCARE TOGETHER<sup>®</sup>

 **SANOFI**

 **Takeda**

 **Xcenda**<sup>®</sup>  
AmerisourceBergen



## AMCP STAFF

### KEVIN BRUNS

*Vice President,  
Communications & Marketing*

### SUSAN A. CANTRELL, RPh, CAE

*Chief Executive Officer*

### MARY JO CARDEN, RPh, JD

*Vice President,  
Government & Pharmacy Affairs*

### CHARLIE DRAGOVICH, BS Pharm

*Vice President,  
Strategic Alliances & Corporate Services*

### FAHIM FARUQUE, PharmD Candidate 2018

*Pharmacy Affairs Associate*

### CAROLINE HUBER, MPH

*Associate Director & Research Scientist,  
Precision Health Economics*

### LAUREN LYLES, PharmD

*Manager of Pharmacy Affairs &  
New Practitioner Programs*

### ZAIN MADHANI

*Program Coordinator,  
Government & Pharmacy Affairs*

### NOREEN MATTHEWS, BSN, MBA

*Program Management  
American Medical Communications*

### TERRY RICHARDSON, PharmD, BCACP

*Director, Product Development*

### SOUMI SAHA, PharmD, JD

*Director, Pharmacy and Regulatory Affairs*

### TRICIA LEE WILKINS, PharmD, MS, PhD

*Director, Pharmacy Affairs*

## THANK YOU

To our distinguished participants and guests. The Academy of Managed Care Pharmacy looks forward to holding more partnership forums focused on issues of greatest importance to our 8,000 members, the more than 270 million Americans covered by a pharmacy benefit, and other health care stakeholders.



### ROBYN CARSON, MPH

*Executive Director, Patient-Centered Outcomes Research  
Allergan*

Robyn has worked in the pharmaceutical industry conducting health economics and outcomes research for 11 years and has recently transitioned to a new role at Allergan, leading the establishment of the new Patient Centered Outcomes Research (PCOR) function. PCOR will focus on optimizing the incorporation of the patient voice into Allergan's development programs and developing innovative strategies to bridge the gaps between clinical research and clinical practice through integration of patient-centered outcomes research and tools in real world settings. This new role merges Robyn's strategic, technical and regulatory expertise with her passion for development of innovative products that will enrich patients' lives. In addition, Robyn is a leader in the cross-industry Critical Path Institute PRO Consortium, co-chairing two initiatives aimed at developing gold standard instruments to assess treatment benefit for new treatments in functional dyspepsia and the irritable bowel syndrome.



### RICHARD H. STANFORD, PharmD, MS

*Senior Director, US Value Evidence and Outcomes  
GlaxoSmithKline*

Richard is Director of the GSK/UNC health outcomes fellowship program and is an Adjunct Assistant Professor within the Division of Pharmaceutical Outcomes and Policy at University of North Carolina-Chapel Hill Eshelman School of Pharmacy. He has authored over 80 peer reviewed publications including papers in The American Journal of Respiratory and Critical Care Medicine, Journal of Allergy and Clinical Immunology and Chest. Richard received his BS and PharmD degrees from UNC-Chapel Hill, an MS in Preventive Medicine from The University of Iowa College of Medicine, where he completed fellowships in pharmacotherapy and health outcomes research.



### SHEILA M. THOMAS, PharmD, RPh

*Senior Director, Global Health Economics and Value Assessment  
Sanofi*

Sheila is Senior Director, Global Health Economics and Value Assessment, Value Frameworks Engagement at Sanofi. She has more than 17 years of professional health economics and outcomes research (HEOR) experience in pharmaceutical industry, building and leading field-based and in-house Medical and HEOR functions. Her responsibilities include US and global evidence generation and communicating the value of health technology to various key stakeholders for pipeline and marketed products across multiple therapeutic areas. She is also an Assistant Clinical Professor at The Ohio State University College of Pharmacy. Prior to joining industry, she held various leadership roles in managed care, Medicaid and public health, including serving on the Ohio Medicaid Drug Utilization and Review committee, two consecutive seven year appointments to the Ohio Public Health Council and is currently serving on the Ohio Public Health Advisory Board.

**Additional Support Provided By:**





675 N WASHINGTON STREET • SUITE 220 • ALEXANDRIA, VA 22314  
[www.amcp.org](http://www.amcp.org)